You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 142 No. 9, September 2006 TABLE OF CONTENTS
  Archives
  •  Online Features
  Correspondence
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Topic Collections
 •Dermatology
 •Dermatologic Disorders
 •Granulomas
 •Transplantation
 •Bone Marrow Transplantation
 •Immunology
 •Immunologic Disorders
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

VIGNETTES
Atypical Early Follicular Graft-vs-Host Disease

Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Follicular graft-vs-host disease (GVHD) was probably first reported in 1984.1 Clinically acute follicular GVHD was described as an eruption similar to a bacterial or fungal folliculitis following allogenic bone marrow transplantation (BMT).2 Cases of clinically acute and chronic follicular GVHD have been described.3-6 We report the unexpected finding of follicular lichenoid GVHD in a biopsy specimen from a nonspecific lesion that appeared on a patient on the 18th day after BMT.

Report of a Case

A 39-year-old woman with acute lymphocytic leukemia, L2type, Philadelphia chromosome positive, and common acute lymphoblastic leukemia antigen positive, in complete remission was treated with an HLA-matched allogenic BMT from her brother following conditioning with intravenous cyclophosphamide (60 mg/kg per day) on days 6 and 5 before BMT and total body irradiation from days 4 to 1 before BMT. Prophylactic treatment against GVHD included intravenous cyclosporin A (1.5 mg/kg every 12 hours) from day 0 and methotrexate, 15 mg/m2 . . . [Full Text of this Article]


Comment

AUTHOR INFORMATION
Rebeca Goiriz, MD; Yolanda Delgado-Jiménez, MD; Pablo Fernández-Peñas, MD, PhD; Javier Fraga, MD, PhD; Amaro García-Diez, MD, PhD; Jesús Fernández-Herrera, MD, PhD



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2006 American Medical Association. All Rights Reserved.